0001558370-20-000846.txt : 20200214 0001558370-20-000846.hdr.sgml : 20200214 20200214164649 ACCESSION NUMBER: 0001558370-20-000846 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20200212 ITEM INFORMATION: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 20621286 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 8-K 1 imgn-20200113x8k3d7e658.htm 8-K
0000855654false00008556542020-02-122020-02-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

​

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported): February 12, 2020

​

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

​

Massachusetts

0-17999

04-2726691

​

​

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

​

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices) (Zip Code)

​

Registrant's telephone number, including area code: (781) 895-0600

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

​

​

Title of Each Class

    

Trading Symbol

    

Name of Each Exchange on Which Registered

​

​

Common Stock, $.01 par value

​

IMGN

​

NASDAQ Global Select Market

​

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

ITEM 5.05. – AMENDMENTS TO THE REGISTRANT’S CODE OF ETHICS, OR WAIVER OF A PROVISION OF THE CODE OF ETHICS.

​

On February 12, 2020, the Audit Committee of the Board of Directors of ImmunoGen, Inc. (also referred to as “we” and “our”) approved amendments to its code of corporate conduct (the “Code”). The Code applies to all of our directors, executive officers and employees. As part of our corporate governance practices, we periodically review the Code and its separate Senior Officer and Financial Personnel Code of Ethics (“SOFP Code”). Following its most recent review, the Audit Committee approved amendments to the Code to add a separate books and records – financial reporting section, which was derived from the SOFP Code, and expand the Code’s compliance with laws and regulations section.

​

As a result of the amendments to the Code to include matters previously covered by the SOFP Code, the Audit Committee also terminated the separate SOFP Code.

​

The amendment to the Code and termination of the SOFP Code did not result in any explicit or implicit waiver of any provision of the Code or the SOFP Code in effect prior to the actions of the Audit Committee discussed above. The foregoing description of the Code does not purport to be complete and is qualified in its entirety by reference to the full text of the Code, which is incorporated herein by reference and is available on the Company’s website at www.immunogen.com in the “Investors and Media” section under the heading “Corporate Governance”. The other contents of our website are not incorporated by reference herein or made a part hereof for any purpose.

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

ImmunoGen, Inc.

​

(Registrant)

​

​

Date: February 14, 2020

/s/ David G. Foster

​

​

​

David G. Foster

​

Vice President, Finance

​

​

​

​

​

 EX-101.SCH 2 imgn-20200113.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 imgn-20200113_lab.xml EX-101.LAB EX-101.PRE 4 imgn-20200113_pre.xml EX-101.PRE JSON 5 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "imgn-20200113x8k3d7e658.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "imgn-20200113x8k3d7e658.htm" ] }, "labelLink": { "local": [ "imgn-20200113_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "imgn-20200113_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "imgn-20200113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "imgn", "nsuri": "http://www.immunogen.com/20200113", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "imgn-20200113x8k3d7e658.htm", "contextRef": "Duration_2_12_2020_To_2_12_2020_zejVD_Vjik2VZ8rGsq8hRQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "imgn-20200113x8k3d7e658.htm", "contextRef": "Duration_2_12_2020_To_2_12_2020_zejVD_Vjik2VZ8rGsq8hRQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identificatoin Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 7 0001558370-20-000846-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-20-000846-xbrl.zip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ǯ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end XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information
Feb. 12, 2020
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Feb. 12, 2020
Entity File Number 0-17999
Entity Registrant Name ImmunoGen, Inc.
Entity Incorporation, State or Country Code MA
Entity Tax Identificatoin Number 04-2726691
Entity Address, Address Line One 830 Winter Street
Entity Address, State or Province MA
Entity Address, City or Town Waltham
Entity Address, Postal Zip Code 02451
City Area Code 781
Local Phone Number 895-0600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.01 par value
Trading Symbol IMGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000855654
Amendment Flag false
XML 10 imgn-20200113x8k3d7e658_htm.xml IDEA: XBRL DOCUMENT 0000855654 2020-02-12 2020-02-12 0000855654 false 8-K 2020-02-12 ImmunoGen, Inc. MA 0-17999 04-2726691 830 Winter Street Waltham MA 02451 781 895-0600 false false false false Common Stock, $.01 par value IMGN NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.immunogen.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports imgn-20200113x8k3d7e658.htm imgn-20200113.xsd imgn-20200113_lab.xml imgn-20200113_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false